Department of Radiotherapy, Institut de Cancérologie de la Loire, 108 bis, avenue Albert Raimond, BP 60008, 42271 Saint Priest en Jarez, France.
Invest New Drugs. 2011 Oct;29(5):1111-3. doi: 10.1007/s10637-010-9476-5. Epub 2010 Jun 22.
Recall dermatitis is a rare and poorly understood drug-related event. Activated by exposure to sunlight or Ultraviolet (UV), drug-related phototoxic reactions have been reported with conventional chemotherapy agents or antibiotics.
Here, we report the first case of acute dermatologic photo-induced recall reaction secondary to sorafenib in a patient with renal cell carcinoma.
Four weeks after stopping sorafenib, a patient with renal cell carcinoma developed an acute erythematous and papulomatous eruption restricted to the hands after prolonged solar exposure. The erythematous region was very well demarcated, mimicking the cutaneous syndrome that the patient had presented at time he was receiving sorafenib.
The suppression of the phototoxic reaction by corticosteroids strongly suggests that the immune system may have an important function in photo-recall reactions.
光化性皮炎是一种罕见且了解甚少的药物相关事件。药物光毒性反应可由接触阳光或紫外线(UV)激活,已有报道称常规化疗药物或抗生素会引起这种反应。
在这里,我们报告了首例索拉非尼引起的肾细胞癌患者的急性皮肤科光诱导回忆反应。
在停止服用索拉非尼四周后,一名肾细胞癌患者在长时间暴露于阳光下后,手部出现急性红斑和丘疹性皮疹。红斑区域非常清晰,类似于患者接受索拉非尼治疗时出现的皮肤综合征。
皮质类固醇对光毒性反应的抑制强烈表明,免疫系统可能在光回忆反应中具有重要作用。